10 research outputs found
Interleukin-33 is activated by allergen- and necrosis-associated proteolytic activities to regulate its alarmin activity during epithelial damage
Interleukin (IL)-33 is an IL-1 family alarmin released from damaged epithelial and endothelial barriers to elicit immune responses and allergic inflammation via its receptor ST2. Serine proteases released from neutrophils, mast cells and cytotoxic lymphocytes have been proposed to process the N-terminus of IL-33 to enhance its activity. Here we report that processing of full length IL-33 can occur in mice deficient in these immune cell protease activities. We sought alternative mechanisms for the proteolytic activation of IL-33 and discovered that exogenous allergen proteases and endogenous calpains, from damaged airway epithelial cells, can process full length IL-33 and increase its alarmin activity up to ~60-fold. Processed forms of IL-33 of apparent molecular weights ~18, 20, 22 and 23 kDa, were detected in human lungs consistent with some, but not all, proposed processing sites. Furthermore, allergen proteases degraded processed forms of IL-33 after cysteine residue oxidation. We suggest that IL-33 can sense the proteolytic and oxidative microenvironment during tissue injury that facilitate its rapid activation and inactivation to regulate the duration of its alarmin function
Pharmacokinetics and Pharmacodynamics of Posaconazole for Invasive Pulmonary Aspergillosis: Clinical Implications for Antifungal Therapy
Background. Posaconazole is a triazole with anti-Aspergillus activity. However, little is known about the utility of posaconazole as primary therapy for invasive pulmonary aspergillosis
Azole Resistance of Aspergillus fumigatus Biofilms Is Partly Associated with Efflux Pump Activity▿
This study investigated the phase-dependent expression and activity of efflux pumps in Aspergillus fumigatus treated with voriconazole. Fourteen strains were shown to become increasingly resistant in the 12-h (16- to 128-fold) and 24-h (>512-fold) phases compared to 8-h germlings. An Ala-Nap uptake assay demonstrated a significant increase in efflux pump activity in the 12-h and 24-h phases (P < 0.0001). The efflux pump activity of the 8-h germling cells was also significantly induced by voriconazole (P < 0.001) after 24 h of treatment. Inhibition of efflux pump activity with the competitive substrate MC-207,110 reduced the voriconazole MIC values for the A. fumigatus germling cells by 2- to 8-fold. Quantitative expression analysis of AfuMDR4 mRNA transcripts showed a phase-dependent increase as the mycelial complexity increased, which was coincidental with a strain-dependent increase in azole resistance. Voriconazole also significantly induced this in a time-dependent manner (P < 0.001). Finally, an in vivo mouse biofilm model was used to evaluate efflux pump expression, and it was shown that AfuMDR4 was constitutively expressed and significantly induced by treatment with voriconazole after 24 h (P < 0.01). Our results demonstrate that efflux pumps are expressed in complex A. fumigatus biofilm populations and that this contributes to azole resistance. Moreover, voriconazole treatment induces efflux pump expression. Collectively, these data may provide evidence for azole treatment failures in clinical cases of aspergillosis
Discovery, Characterization, and Structure-Based Optimization of Small-Molecule In Vitro and In Vivo Probes for Human DNA Polymerase Theta
Human DNA polymerase theta (Polθ), which is essential
for
microhomology-mediated DNA double strand break repair, has been proposed
as an attractive target for the treatment of BRCA deficient and other
DNA repair pathway defective cancers. As previously reported, we recently
identified the first selective small molecule Polθ in vitro
probe, 22 (ART558), which recapitulates the phenotype
of Polθ loss, and in vivo probe, 43 (ART812), which
is efficacious in a model of PARP inhibitor resistant TNBC in vivo.
Here we describe the discovery, biochemical and biophysical characterization
of these probes including small molecule ligand co-crystal structures
with Polθ. The crystallographic data provides a basis for understanding
the unique mechanism of inhibition of these compounds which is dependent
on stabilization of a “closed” enzyme conformation.
Additionally, the structural biology platform provided a basis for
rational optimization based primarily on reduced ligand conformational
flexibility
Discovery, Characterization, and Structure-Based Optimization of Small-Molecule In Vitro and In Vivo Probes for Human DNA Polymerase Theta
Human DNA polymerase theta (Polθ), which is essential
for
microhomology-mediated DNA double strand break repair, has been proposed
as an attractive target for the treatment of BRCA deficient and other
DNA repair pathway defective cancers. As previously reported, we recently
identified the first selective small molecule Polθ in vitro
probe, 22 (ART558), which recapitulates the phenotype
of Polθ loss, and in vivo probe, 43 (ART812), which
is efficacious in a model of PARP inhibitor resistant TNBC in vivo.
Here we describe the discovery, biochemical and biophysical characterization
of these probes including small molecule ligand co-crystal structures
with Polθ. The crystallographic data provides a basis for understanding
the unique mechanism of inhibition of these compounds which is dependent
on stabilization of a “closed” enzyme conformation.
Additionally, the structural biology platform provided a basis for
rational optimization based primarily on reduced ligand conformational
flexibility
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
Polθ has been recently identified as a therapeutic target in cancer but specific inhibitors are currently unavailable. Here, the authors identify small molecule inhibitors of Polθ’s polymerase activity which elicit BRCA1/2 synthetic lethality, enhance the effect of PARP inhibitors and target PARP inhibitor resistance caused by 53BP1/Shieldin pathway defects